Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease -February 08, 2024 at 07:02 am EST : vimarsana.com

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease -February 08, 2024 at 07:02 am EST

The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globallySOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 -- Alector, Inc. and GSK plc today...

Related Keywords

United States , South San Francisco , California , Katie Hogan , Arnon Rosenthal , Laura Perry , Dan Budwick , Alector Inc , Nasdaq , Exchange Commission , Chief Executive Officer , Clinical Dementia Rating Sum , Private Securities Litigation Reform Act , Quarterly Report , Markets ,